On one hand, inactivating mutations in the CEBPA gene have been described in about 10% - 15% of AML cases [20] (and rarely in non-hematologic malignancies [20, 21]), and they may result in loss of the protein function. This evidence concerns the gene CEBPA and acute myeloid leukemia.